Is Option Care Health (OPCH) Cheap As Earnings Beat Lifts Its Growth Outlook?

Earnings beat puts Option Care Health in focus

Option Care Health (OPCH) drew fresh attention after reporting quarterly revenue and earnings that exceeded analyst forecasts, with management highlighting the company’s growth trajectory and operational focus despite sector wide pressures.

Option Care Health’s recent earnings beat came after a mixed period for investors, with the share price up 19.26% over 90 days but the year-to-date share price return down 24.13% and the 1-year total shareholder return down 15.01%, which suggests sentiment is rebuilding from a weaker base as investors reassess the company’s growth and risk profile.

Scan how Option Care Health stacks up against other potential breakout opportunities across our hand picked 52 high quality undervalued stocks for ideas with solid fundamentals and room for sentiment to shift.

After a sharp 90 day rebound yet weaker returns over one and three years, the question for Option Care Health now is whether the recent earnings beat marks the start of a catch up phase or reflects gains already made.

Most Popular Narrative: 14.4% Undervalued

Analysts currently see Option Care Health trading below an estimated fair value of $28.58, compared with the latest close at $24.46. This comparison puts the focus firmly on the long term story behind that gap.

Growth in both acute and chronic infusion therapies is outpacing the market, driven by demographic shifts (aging population and higher prevalence of chronic/complex conditions), which is expanding Option Care Health's addressable market and positioning the company for sustained revenue growth.

Read the complete narrative. Read the complete narrative.

Analysts are not just plugging in simple top line growth. The fair value leans on a specific earnings path, margin lift and a future P/E that differs from today. The real story is how those pieces fit together over several years, not just one strong quarter.

Result: Fair Value of $28.58 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Option Care Health still faces therapy mix shifts that could pressure margins, as well as reimbursement changes that might weigh on revenue and earnings consistency.

Find out about the key risks to this Option Care Health narrative.

Another view on Option Care Health’s valuation

The earlier narrative framed Option Care Health as trading below a $28.58 fair value based on analyst assumptions about earnings and margins. Our DCF model points in a different direction. At $24.46, the stock is above an estimated future cash flow value of $18.19, which signals potential overvaluation if those cash flow assumptions hold.

For investors, that split raises a practical question. Which matters more: the earnings path implied by analyst targets or the cash flows implied by our DCF model? And which set of assumptions feels closer to how you think Option Care Health will actually perform over time.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Option Care Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals around Option Care Health, this is the moment to look at the numbers yourself and decide where you stand. Move quickly, review both the concerns and the potential upside, and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Option Care Health?

If Option Care Health has you thinking harder about your portfolio, this is a good moment to widen your search and line up your next potential moves.

• Target reliable cash generators by scanning companies with steady finances through our list of solid balance sheet and fundamentals (53 results) so your shortlist focuses on financial strength.
• Spot potential mispricings early by checking our 21 high quality undiscovered gems before more investors catch on and narrow the opportunity set.
• Prioritise capital preservation by reviewing our 79 resilient stocks with low risk scores and keep your attention on stocks with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com